Min Li, Ph.D., a George Lynn Cross Professor of Medicine, Surgery and Cell Biology at the University of Oklahoma College of Medicine and Associate Director for Global Oncology at OU Health Stephenson Cancer Center, will receive the 2024 Palade Prize from the International Association of Pancreatology.
The Palade Prize, the IAP's most distinguished award for research excellence, recognizes Li's contributions to the field of pancreatology, which is dedicated to discovering new methods of identifying, diagnosing and treating diseases of the pancreas such as pancreatic cancer. The award is named after George E. Palade, who won the Nobel Prize in 1974 for his pioneering work involving a specialized pancreatic cell type.
Li will receive the prize during the IAP annual meeting Dec. 9-12, and he will give a lecture on cancer cachexia and metabolic reprogramming. Li has been continuously funded by the National Cancer Institute, a component of the National Institutes of Health, for the past 15 years, including three active R01 grants.
His contributions to science focus on three areas: Related Stories Western diet accelerates endometriosis growth and disrupts gut health Healthy low-carb diet and time-restricted eating improve weight loss and gut health beyond calorie restriction Diabetes drugs cut asthma attacks by up to 70%, reshaping treatment options Development of a combination therapy for pancreatic cancer using a novel surgical mouse model. As part of this work, his laboratory was.
